In situ PD-L1 expression in oral squamous cell carcinoma is induced by heterogeneous mechanisms among patients
Y Kondo, S Suzuki, S Ono, M Goto, S Miyabe… - International Journal of …, 2022 - mdpi.com
The expression of programmed death ligand-1 (PD-L1) is controlled by complex
mechanisms. The elucidation of the molecular mechanisms of PD-L1 expression is …
mechanisms. The elucidation of the molecular mechanisms of PD-L1 expression is …
A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC
Y Ding, L Chu, Q Cao, H Lei, X Li, Q Zhuang - BMC cancer, 2023 - Springer
Background Tumor microenvironment (TME) is of great importance to regulate the initiation
and advance of cancer. The immune infiltration patterns of TME have been considered to …
and advance of cancer. The immune infiltration patterns of TME have been considered to …
Identification of an endoplasmic reticulum stress-related gene signature to evaluate the immune status and predict the prognosis of hepatocellular carcinoma
D Song, Z Zhou, D Zhang, J Wu, Q Hao, L Zhao… - Frontiers in …, 2022 - frontiersin.org
Liver cancer is the sixth most frequently diagnosed primary malignancy and ranks as the
third leading cause of cancer-related death worldwide in 2020. ER stress also plays a vital …
third leading cause of cancer-related death worldwide in 2020. ER stress also plays a vital …
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways
R Wang, S He, J Long, Y Wang, X Jiang… - … Hematology & Oncology, 2024 - Springer
The interaction between programmed cell death ligand 1 (PD-L1), which is expressed on the
surface of tumor cells, and programmed cell death 1 (PD-1), which is expressed on T cells …
surface of tumor cells, and programmed cell death 1 (PD-1), which is expressed on T cells …
A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
J Le Naour, Z Sztupinszki, V Carbonnier… - …, 2022 - Taylor & Francis
The anticancer immune response is shaped by immunogenic cell stress and death
pathways. Thus, cancer cells can release danger-associated molecular patterns that act on …
pathways. Thus, cancer cells can release danger-associated molecular patterns that act on …
Circadian Regulator‐Mediated Molecular Subtypes Depict the Features of Tumor Microenvironment and Indicate Prognosis in Head and Neck Squamous Cell …
L Aye, Z Wang, F Chen, Y Xiong, J Zhou… - Journal of …, 2023 - Wiley Online Library
Introduction. Circadian rhythm is involved in multiple biological activities and implicated in
cancer development. However, the role of circadian rhythm in head and neck squamous cell …
cancer development. However, the role of circadian rhythm in head and neck squamous cell …
[HTML][HTML] 8-Gene signature related to CD8+ T cell infiltration by integrating single-cell and bulk RNA-sequencing in head and neck squamous cell carcinoma
S Zhang, W Zhang, J Zhang - Frontiers in Genetics, 2022 - frontiersin.org
Background: CD8+ T cells, a critical component of the tumor immune microenvironment,
have become a key target of cancer immunotherapy. Considering the deficiency of robust …
have become a key target of cancer immunotherapy. Considering the deficiency of robust …
HER2 and HER3 as therapeutic targets in head and neck cancer
R Saddawi-Konefka, S Schokrpur, AJ Lui… - The Cancer …, 2022 - journals.lww.com
Work over the past several decades has identified that aberrations in the ErbB signaling
pathways are key drivers of oncogenesis, and concurrent efforts to discover targetable …
pathways are key drivers of oncogenesis, and concurrent efforts to discover targetable …
Combination strategy exploration for prior treated recurrent or metastatic nasopharyngeal carcinoma in the era of immunotherapy
Y Jiang, C Chen, G Liu, T Fang, N Lu, W Bei, S Dong… - Scientific Reports, 2024 - nature.com
To assess the efficacy and safety of the combination of immune checkpoint inhibitors (ICIs)
and target therapy (anti-angiogenesis or EGFR inhibitors) as a second-line or subsequent …
and target therapy (anti-angiogenesis or EGFR inhibitors) as a second-line or subsequent …
Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111 …
SP Beyaert, AE Loriot, ND Huyghe, RM Goebbels… - Clinical Cancer …, 2023 - AACR
Abstract Purpose: The EORTC-90111–24111 phase II window study evaluated afatinib
versus no preoperative treatment in patients with primary squamous cell carcinoma of the …
versus no preoperative treatment in patients with primary squamous cell carcinoma of the …